STATURE: Relationship Between Oral DMT Burden and Adherence in MS

Sponsor

Monash University (Other)

Overall Status

Enrolling by invitation

CT.gov ID

NCT04676204

Collaborator

(none)

323

Enrollment

Location

69.5

Anticipated Duration (Months)

4.6

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

STATURE is a prospective observational four-arm translation multi-site study that will run for approx. 4.5 years. The primary aim is to measure treatment burden and its relationship to medication adherence across four self-administered oral disease-modifying therapies (cladribine, dimethyl fumarate, fingolimod, and teriflunomide) in multiple sclerosis (MS). The information gained will assist prescribing decision-making; accounting for medication burden at a patient level and potential implications on medication adherence and persistence, thus minimising primary and secondary healthcare costs. Three-hundred and twenty-three individuals with MS will be recruited into the study. Patient-reported outcome measures will be administered via Qualtrics, a secure online data collection tool. Medicare and pharmaceutical benefits scheme (PBS) data will also be collected.

Condition or Disease	Intervention/Treatment	Phase
Multiple Sclerosis Adherence, Medication	Drug: Cladribine Drug: Dimethyl fumarate Drug: Fingolimod Drug: Teriflunomide

Study Design

Study Type:

Observational

Anticipated Enrollment :

323 participants

Observational Model:

Other

Time Perspective:

Prospective

Official Title:

STATURE: A Prospective Observational Study of the relationShip beTween Oral DMT bURden and adhErence in People With MS

Actual Study Start Date :

Sep 25, 2020

Anticipated Primary Completion Date :

Nov 19, 2025

Anticipated Study Completion Date :

Jul 11, 2026

Arms and Interventions

Arm	Intervention/Treatment
Cladribine Participants with MS commencing cladribine disease modifying treatment as clinically prescribed.	Drug: Cladribine Cladribine is a purine antimetabolite indicated for the treatment of relapsing forms of multiple sclerosis, to include relapsing-remitting disease and active secondary progressive disease, in adults. Other Names: Mavenclad
Dimethyl Fumarate Participants with MS commencing dimethyl fumarate disease modifying treatment as clinically prescribed.	Drug: Dimethyl fumarate Dimethyl fumarate is indicated for the treatment of relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults Other Names: Tecfidera
Fingolimod Participants with MS commencing fingolimod disease modifying treatment as clinically prescribed.	Drug: Fingolimod Fingolimod is a sphingosine 1-phosphate receptor modulator indicated for the treatment of patients with relapsing forms of multiple sclerosis to reduce the frequency of clinical exacerbations and to delay the accumulation of physical disability. Other Names: Gilenya
Teriflunomide Participants with MS commencing teriflunomide disease modifying treatment as clinically prescribed.	Drug: Teriflunomide Teriflunomide is a pyrimidine synthesis inhibitor indicated for the treatment of patients with relapsing forms of multiple sclerosis. Other Names: Aubagio

Outcome Measures

Primary Outcome Measures

Medication Burden [24-months]
Identification of medication burden will be calculated into indices of pre-workup and monitoring time, refill and administration and side-effects. This will allow the development of an indices of overall perceived burden, as well as sub-indices of specific perceived burden.
Medication Adherence (MPR) [24-months]
Identification of medication adherence, persistence and switching between oral DMTs will be calculated as the medication possession ratio (MPR) collected from pharmaceutical benefit scheme claims over the 24-month enrollment period. In addition, basic self-reported adherence and discontinuation will be collected.
Medication Adherence (PDC) [24-months]
Identification of medication adherence, persistence and switching between oral DMTs will be calculated as the proportion of days covered (PDC) collected from pharmaceutical benefit scheme claims over the 24-month enrollment period. In addition, basic self-reported adherence and discontinuation will be collected.

Secondary Outcome Measures

Multiple Sclerosis Quality of Life-54 (MSQOL-54) [24-Months]
The Multiple Sclerosis Quality of Life-54 (MSQOL-54) is a structured, self-report questionnaire examining quality of life that contains 54-items, generating 12 subscales with two summary scores (physical health and mental health) and two additional single-item measures (satisfaction with sexual function and change in health). In scoring the MSQOL-54, two summary scores (physical and mental health) are produced from a weighted combination of scale scores, where scale scores range from 0 to 100, with higher scale score indicating improved quality of life. Quality of life (QoL) is being utilised as an outcome measure to identify whether QoL is predicted by 24-month MPR/PDC adherence and persistence.

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 99 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

18 years or older.
A confirmed diagnosis of multiple sclerosis.
Commencement (switching or newly prescribed) of one of the 4 following DMTs within the previous 2-months: cladribine, dimethyl fumarate, fingolimod, teriflunomide.
Able to read and write in English.
Access to an internet connection and computer facilities, required to complete assessments.

Exclusion Criteria:

Use of any other DMT than cladribine, dimethyl fumarate, fingolimod, teriflunomide.
Comorbid neurological condition.
Severe cognitive or psychological dysfunction deemed to interfere with the person's ability to undertake study requirements, as determined by their MS clinic treatment team (neurologist; MS nurse).